Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
In August, Biogen signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for the deal. ... Biogen deal.
Latest news
-
GSK and Vir Biotech expand phase 3 COVID-19 antibody study
Vir Biotech has also signed a deal with Biogen for the process development and manufacturing of its antibodies for COVID-19. ... The Biogen agreement builds on Vir Biotech’s additional manufacturing agreements with China-based WuXi Biologics and Incheon
-
FDA sets November date for expert panel review of Biogen’s aducanumab
submission. Last October, Biogen announced its intention to file aducanumab for approval only a few months after abandoning the drug in phase 3. ... participants. However, Biogen surprised investors when it announced that a closer analysis of a subset of
-
Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month
In May, Vir signed a deal with Biogen to develop and manufacture antibodies for the potential treatment of COVID-19. ... This included VIR-7831 and another antibody candidate, VIR-7832. Under the terms of this agreement, Biogen will perform process
-
Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track
The road to approval has been a rocky one for Biogen’s drug, with many twists and turns along the way. ... If aducanumab is approved, Biogen can expect billions of dollars in annual revenues.
-
Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi
The first drug to reach the market for SMA was Biogen’s Spinraza (nusinersen) back in 2016.
More from news
Approximately 128 fully matching, plus 310 partially matching documents found.
Latest Intelligence
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
-
Great expectations: the urgent need for common purpose in Alzheimer’s disease
Biogen surprised the world last autumn by announcing a re-evaluation of its latest aducanumab trial and the company is now expected to apply for regulatory approval.
-
Can protein degraders unlock ‘undruggable’ drug targets?
C4 also has a collaboration in place with Biogen focusing on neurological conditions such as Alzheimer’s disease and Parkinson’s disease worth up to $415m.
More from intelligence
Approximately 2 fully matching, plus 44 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
-
Acumen appoints new strategy director
Thomas Bols will focus on reinforcing Acumen’s healthcare practice
More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.
Latest from PMHub
-
Attigo (part of the Mednet Group)
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
Strategic planning - to ensure sustained engagement and ongoing success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, HRA Pharma, Janssen, Leo Pharma, Mylan,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
-
Wallace Health
Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Novartis’ MS therapy Mayzent approved by NICE
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- The Truth about Doctors
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue
- Researchers say COVID-19 antibody levels have fallen rapidly in the UK
- Exploring the potential of eosinophils
- Eliminating pharmaceutical rebates, is this déjà vu?
- Bayer pays an initial $2bn for gene therapy firm AskBio
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
- Eliminating pharmaceutical rebates, is this déjà vu?
- By Andrew Parece and Matthew Majewski...
- Patients are ready to embrace decentralised clinical trials, are you?
- Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Quick links
Infographics
